LAURUSLABS.BO
Company Description
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Track Record
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.13B | 55.54B | 50.41B | 60.41B | 49.36B | 48.14B | 28.32B | 22.92B | 20.56B | 19.05B | 17.78B | 13.27B |
| Net Income | 8.89B | 3.58B | 1.61B | 7.90B | 8.28B | 9.84B | 2.55B | 937.64M | 1.68B | 1.90B | 1.34B | 683.69M |
| EPS | 16.47 | 6.65 | 2.98 | 14.69 | 15.42 | 18.36 | 4.79 | 1.77 | 3.17 | 4.16 | 4.27 | 2.21 |
| Free Cash Flow | 3.89B | (393.50M) | (126.20M) | 37.40M | 342.60M | 442.30M | 1.25B | 434.01M | (486.18M) | 544.86M | (1.44B) | N/A |
| FCF / Share | 7.22 | -0.73 | -0.23 | 0.07 | 0.64 | 0.82 | 2.35 | 0.81 | -0.91 | 1.19 | -2.92 | N/A |
| Operating CF | 14.59B | 6.02B | 6.66B | 9.94B | 9.11B | 7.33B | 3.47B | 2.98B | 3.42B | 3.32B | 1.93B | N/A |
| Total Assets | 105.11B | 93.36B | 83.87B | 76.60B | 69.68B | 57.51B | 37.50B | 33.31B | 30.17B | 26.53B | 23.03B | N/A |
| Total Debt | 25.18B | 27.64B | 25.77B | 20.15B | 17.77B | 14.82B | 10.79B | 10.36B | 9.80B | 8.42B | 10.29B | N/A |
| Cash & Equiv | 1.14B | 995.40M | 1.39B | 456.70M | 753.50M | 484.60M | 16.88M | 29.68M | 30.04M | 24.23M | 128.06M | N/A |
| Book Value | 53.00B | 44.73B | 41.11B | 40.38B | 33.51B | 25.98B | 17.70B | 15.58B | 14.83B | 13.30B | 8.52B | N/A |
| Return on Equity | 0.17 | 0.08 | 0.04 | 0.20 | 0.25 | 0.38 | 0.14 | 0.06 | 0.11 | 0.14 | 0.16 | N/A |
| Metric | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.12B | 17.78B | 16.53B | 15.70B | 17.20B | 14.15B | 12.24B | 11.95B | 14.40B | 11.95B | 12.24B | 11.82B |
| Net Income | 2.79B | 2.52B | 1.95B | 1.63B | 2.34B | 923.00M | 198.40M | 125.10M | 756.10M | 231.40M | 369.50M | 248.50M |
| EPS | 5.17 | 4.66 | 3.61 | 3.02 | 4.34 | 1.71 | 0.37 | 0.23 | 1.40 | 0.43 | 0.69 | 0.46 |
| Free Cash Flow | N/A | N/A | 6.04B | 0 | 0 | 0 | 0 | 0 | 0 | 1.97B | 1.87B | 1.81B |
| FCF / Share | N/A | N/A | 11.19 | N/A | N/A | N/A | N/A | N/A | N/A | 3.66 | 3.44 | 3.35 |
| Operating CF | N/A | N/A | 10.93B | 0 | 0 | 0 | 0 | 0 | 0 | 1.97B | 1.87B | 1.81B |
| Total Assets | 105.11B | N/A | 94.15B | 0 | 93.36B | 0 | 87.29B | 0 | 83.87B | 0 | 80.58B | 0 |
| Total Debt | 25.18B | N/A | 22.12B | 0 | 26.26B | 0 | 27.89B | 0 | 25.77B | 0 | 21.34B | 0 |
| Cash & Equiv | 1.14B | N/A | 633.80M | 0 | 506.40M | 0 | 449.20M | (1.42B) | 1.39B | (671.60M) | 667.40M | (484.60M) |
| Book Value | 53.00B | N/A | 48.05B | 46.03B | 44.73B | 41.44B | 41.34B | 41.16B | 41.11B | 40.43B | 40.30B | 40.49B |
| Return on Equity | 0.05 | N/A | 0.04 | 0.04 | 0.05 | 0.02 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 |